Welcome to our dedicated page for Orexo Ab news (Ticker: ORXOY), a resource for investors and traders seeking the latest updates and insights on Orexo Ab stock.
Orexo AB (ORXOY) generates a steady stream of news related to pharmaceutical development, drug delivery technology and commercial progress. Company announcements emphasize its proprietary AmorphOX powder-based platform, clinical studies of intranasal rescue medications, and collaborations that extend its technology to new therapeutic areas.
Readers of this news feed can follow updates on Orexo’s work in opioid use disorder treatments in the U.S. market, as well as development projects such as OX124, a high-dose naloxone rescue medication for opioid overdose. Interim reports provide context on revenues, cash flow, and the performance of the U.S. Commercial segment, alongside commentary from management on business development and regulatory interactions.
A significant portion of Orexo’s recent news focuses on the AmorphOX platform and its application to intranasal formulations. This includes clinical and preclinical results for OX640, a nasal epinephrine powder product for severe allergic reactions including anaphylaxis, and preclinical data on powder-based intranasal semaglutide formulations. Company releases describe pharmacokinetic and pharmacodynamic findings, such as absorption profiles, plasma levels and effects on blood pressure and heart rate.
Another recurring news theme is collaboration on nasal powder vaccines. Orexo reports on its partnership with Abera Bioscience to combine AmorphOX with a vaccine platform for mucosal vaccines, including intranasal influenza vaccine candidates. Updates cover proof-of-concept immune response data and the potential implications for vaccine stability and administration.
Investors and observers can also track corporate governance items, such as the composition of the nomination committee for the annual general meeting, and participation in healthcare conferences. Bookmarking this page allows users to monitor Orexo’s clinical milestones, technology developments and financial disclosures as they are released.
Orexo (OTCQX: ORXOY / STO: ORX; symbol provided: ORXOF) invites investors, analysts and media to its R&D Day on March 24, 2026 in Stockholm. Management will outline updated strategy after the US Zubsolv divestment and present R&D priorities centred on the AmorphOX drug delivery platform.
Agenda highlights include sessions on AmorphOX applications, OX640 intranasal epinephrine, OX390 intranasal rescue medication and a prerecorded expert perspective on xylazine/medetomidine/fentanyl risks. Registration available via the company's R&D Day webpage.
Orexo (OTCQX:ORXOY / STO:ORX, ADR: ORXOF) announced organizational and management changes on March 6, 2026 following the divestment of Zubsolv in the US and a renewed focus on advancing development programs and the AmorphOX technology.
Lisa Moore will become SVP, Products and Portfolio Strategy, reporting to the CEO and joining the management team; Robert DeLuca will retire from his President, Orexo US Inc. role in May 2026 and continue in an advisory capacity for the Zubsolv transition. Orexo will present at its R&D Day on March 24, 2026.
Orexo AB (OTCQX: ORXOY) has announced positive results from a preclinical pharmacokinetic study using its AmorphOX® technology to develop intranasal formulations of semaglutide. The study compared three powder-based intranasal formulations with oral (Rybelsus®) and injectable (Wegovy®) versions.
Two of the AmorphOX powder formulations demonstrated a sevenfold increase in plasma values compared to the oral tablet, with lower variability in plasma concentration. While the intranasal formulations showed lower values than injectable delivery, they offer potential advantages including needle-free administration, no refrigeration requirements, and possibly extended dosing schedules.
The successful formulation of large peptides like semaglutide supports Orexo's updated strategy to focus on larger molecules including peptides, proteins, and vaccines.
Orexo AB (ORXOY) has announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine using their AmorphOX technology. The study, conducted in partnership with Abera Bioscience, tested an influenza vaccine candidate in rats using both liquid nasal solution and intranasal powder formulations.
The results showed that both formulations successfully induced strong systemic antibody response in serum (IgG) and locally in the nose and lungs (IgA), with no difference in immune response between the two delivery methods. The powder formulation, utilizing AmorphOX technology, offers potential advantages including cost-efficiency and thermostability without cold chain requirements.
This development represents a significant milestone in vaccine delivery innovation, particularly relevant for pandemic scenarios, as powder-based vaccines could enable simplified logistics and potential self-administration during mass vaccination campaigns.
Orexo AB (STO: ORX, OTCQX: ORXOY) announced positive topline results from clinical study OX640-002, evaluating their nasal rescue medication OX640, a powder-based epinephrine treatment for allergic reactions including anaphylaxis. The cross-over study involved 30 subjects and compared two doses of OX640 against an intramuscular injection reference product.
Key findings showed that OX640 treatments achieved clinically relevant epinephrine plasma levels faster than the intramuscular reference. Notably, absorption was significantly faster under allergic rhinitis conditions compared to normal conditions, demonstrating efficacy in patients with airway symptoms. The treatment produced more pronounced increases in blood pressure and heart rate compared to intramuscular injection. Safety profiles aligned with known epinephrine pharmacology, with only transient and tolerable local effects reported.
Orexo AB (STO: ORX, OTCQX: ORXOY) has entered into a collaboration with Abera Bioscience to develop nasal powder vaccines using Orexo's AmorphOX® technology. The partnership aims to develop mucosal vaccines, initially focusing on Abera's influenza vaccine candidate. The AmorphOX technology has demonstrated potential to improve stability and efficacy of various active ingredients, from small molecules to larger biomolecules like vaccines.
The collaboration is funded through Abera's previously received grants, primarily from CEPI (Coalition for Epidemic Preparedness Innovation). The partnership represents a strategic step in leveraging AmorphOX's scalability, combining Orexo's powder formulation expertise with Abera's 30+ years of vaccine development experience.
Orexo has initiated a new clinical study (OX640-002) for OX640, an intranasal rescue medication for severe allergic reactions using powder-based epinephrine. The study will evaluate OX640's performance in 30 participants with allergic rhinitis through a cross-over design with four treatment periods. This follows positive phase 1 results where OX640 showed comparable absorption and effects to intramuscular auto-injectors.
The study will assess epinephrine absorption with and without allergic symptoms, comparing it to a commercial intramuscular product. The study cost is estimated at SEK 11 million, with completion expected in 2024 and results in early 2025.
Orexo reported Q3 2024 financial results with total net revenues of SEK 136.5m, down from SEK 156.1m in Q3 2023. The company posted a negative EBITDA of SEK -0.7m, improving from SEK -9.5m last year. US Commercial segment revenues declined to SEK 131.0m from SEK 140.4m. Net earnings deteriorated to SEK -41.9m from SEK -33.3m. The FDA requested additional technical data for OX124, their high-dose naloxone rescue medication. Despite challenges, including higher legal costs and lower Zubsolv sales, the company maintained its 2024 financial guidance and initiated a phase 1 study for OX640 in allergic rhinitis patients.
Orexo has announced the formation of its Nomination Committee for the Annual General Meeting (AGM) scheduled for May 8, 2025. The committee comprises four members: Henrik Kjaer Hansen (Chairman, appointed by Novo Holdings A/S), Claus Berner Møller (appointed by The Danish Labour Market Supplementary Pension, ATP), Stefan Hansson (private investor), and James Noble (Chairman of the Board of Orexo).
The Nomination Committee represents approximately 34 percent of the company's voting rights as of August 31, 2024. Their responsibilities include preparing proposals for the AGM regarding the Chairman of the meeting, Chairman of the Board, Board members, fees, auditor fees, and principles for the Nomination Committee's composition. Shareholders can submit proposals to the committee via email by March 7, 2025.